Abacavir/Lamivudine/Dolutegravir
Indication :
Dosing :
Available as (600 mg/300 mg/50 mg) tablet.
>40 kg: 1 tablet a day.
<40 kg: Safety not established.
Adverse Effect :
Please see the adverse effects of abacavir, lamivudine and dolutegravir.
Hepatic Dose :
Abacavir: Moderate to severe hepatic impairment: Use is contraindicated
Lamivudine: No dosage adjustments required. Use with caution in patients with decompensated liver disease.
Dolutegravir: Mild to moderate hepatic impairment: No dosage adjustment necessary. Severe hepatic impairment: Drug use not recommended.
Pediatric Oncall
08/26/2024 22:28:35
08/26/2024 22:28:35
Abacavir/Lamivudine/Dolutegravir